The Mito Fund

Friederike Fabritius, the fund's founder, leads investment decisions. She brings a neuropsychology background from McKinsey and co-founded the consulting firm Fabritius & Partner, which informs her scientific due-diligence approach in mitochondrial therapeutics.

The fund sources through academic mitochondrial biology networks and European-US biotech hubs, rather than through generalist venture channels. Fabritius's scientific background and the fund's narrow thesis attract founders working specifically on mitochondrial mechanisms, generating referral-based deal flow from research institutions.

It is structured as a single-family office — there is no evidence of external limited partners, closed-end fund vehicles, or capital-raising from institutional investors. The fund's lack of external LP pressure allows it to hold concentrated, long-duration positions in preclinical science that traditional venture funds typically avoid.

The fund targets preclinical and early clinical-stage companies — before conventional biotech venture funds typically engage. Its portfolio includes Phase 1 and Phase 2 clinical assets focused on mitochondrial dysfunction, with confirmed exposure to companies like Stealth Biotherapeutics during their mid-stage development.

The fund avoids any therapeutic area not directly linked to mitochondrial biology. This means it does not invest in oncology, immunology, or medical devices unless the mechanism specifically implicates mitochondrial dysfunction. This deliberate exclusion concentrates risk within a single biological pathway.